Shanghai Junshi Biosciences Co (1877) Q1 2025 earnings summary

Executive summary

• Operating income rose 31.46% year-over-year to RMB 500.6 million, driven by increased sales of commercialized drugs, especially toripalimab injection, which saw domestic sales rise 45.72% to RMB 447 million.

• Net loss attributable to shareholders narrowed to RMB 234.9 million from RMB 283.0 million year-over-year, reflecting improved operational efficiency and focused R&D investment.

• Cash and cash equivalents plus financial assets for trading totaled RMB 3,022 million, indicating strong liquidity.

Financial highlights

• Operating income: RMB 500.6 million, up 31.46% year-over-year.

• Net loss attributable to shareholders: RMB 234.9 million, improved from RMB 283.0 million loss year-over-year.

• Basic and diluted EPS: -0.24 RMB, up from -0.29 RMB year-over-year.

• Net cash flow from operating activities: -RMB 24.3 million, a significant improvement from -RMB 376.6 million year-over-year.

• R&D investment: RMB 350.6 million, 70.03% of operating income.

Outlook and guidance

• Plans to accelerate early-stage pipeline exploration and initiate pivotal clinical trials for multiple products in 2025.

• Continued focus on quality and efficiency enhancement, with expectations for further commercialization competitiveness and income-generating capacity.